Mississippi Senate Bill SB2544

Mississippi 2026 Regular Session

• Introduced: 1/19/26
• Refer: 1/19/26
• Failed: 2/3/26

Caption

Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.

Impact

The regulations introduced by SB2544 will require the Board of Pharmacy to have expanded inspection capabilities to ensure compliance by entities engaging in drug compounding. It obligates these entities to maintain comprehensive records of their bulk drug substances for at least two years after the expiry of the last batch. This increased scrutiny is designed to safeguard public health by ensuring that compounded drugs meet stringent safety and quality metrics, potentially reducing the risk of adverse drug reactions stemming from poorly compounded medications.

Summary

Senate Bill 2544, also known as the Mississippi Active Pharmaceutical Ingredient Quality Assurance Act, aims to enhance the regulation of compounded drugs in the state. It establishes that it is unlawful for any individual or entity to sell, transfer, or distribute compounded drugs unless they adhere to strict standards related to bulk drug substances. This includes compliance with the applicable United States Pharmacopoeia standards and obtaining necessary certifications that ensure the quality and safety of the compounded product.

Contention

There may be concerns regarding the increased regulatory burden on pharmacies and compounding entities due to the stringent requirements for the sale of compounded drugs. The implementation of these regulations could potentially lead to higher operational costs for pharmacies, which may be passed on to consumers. The bill stipulates significant penalties for non-compliance, including substantial fines per dose of illegally compounded drugs and possible revocation of business licenses, raising fears among smaller compounding entities about their ability to maintain compliance and survive financially.